BioCryst Quick Ratio vs Inventory Turnover Analysis
| BCRX Stock | USD 4.38 0.03 0.68% |
BioCryst Pharmaceuticals financial indicator trend analysis is way more than just evaluating BioCryst Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether BioCryst Pharmaceuticals is a good investment. Please check the relationship between BioCryst Pharmaceuticals Quick Ratio and its Inventory Turnover accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.
Quick Ratio vs Inventory Turnover
Quick Ratio vs Inventory Turnover Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of BioCryst Pharmaceuticals Quick Ratio account and Inventory Turnover. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between BioCryst Pharmaceuticals' Quick Ratio and Inventory Turnover is -0.4. Overlapping area represents the amount of variation of Quick Ratio that can explain the historical movement of Inventory Turnover in the same time period over historical financial statements of BioCryst Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of BioCryst Pharmaceuticals' Quick Ratio and Inventory Turnover is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Quick Ratio of BioCryst Pharmaceuticals are associated (or correlated) with its Inventory Turnover. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Inventory Turnover has no effect on the direction of Quick Ratio i.e., BioCryst Pharmaceuticals' Quick Ratio and Inventory Turnover go up and down completely randomly.
Correlation Coefficient | -0.4 |
| Relationship Direction | Negative |
| Relationship Strength | Very Weak |
Quick Ratio
A measure of a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as (current assets - inventories) divided by current liabilities.Inventory Turnover
A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.Most indicators from BioCryst Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into BioCryst Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.At this time, BioCryst Pharmaceuticals' Selling General Administrative is fairly stable compared to the past year. Tax Provision is likely to rise to about 1.9 M in 2024, whereas Issuance Of Capital Stock is likely to drop slightly above 324.9 K in 2024.
| 2021 | 2022 | 2023 | 2024 (projected) | Total Operating Expenses | 327.6M | 412.7M | 428.8M | 450.2M | Cost Of Revenue | 7.3M | 6.6M | 6.3M | 9.2M |
BioCryst Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
BioCryst Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
BioCryst Pharmaceuticals fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 175.3M | 334.7M | 588.2M | 550M | 517.0M | 542.8M | |
| Short Long Term Debt Total | 84.7M | 124.7M | 593.2M | 741.5M | 848.7M | 891.1M | |
| Other Current Liab | 36.3M | 55.6M | 72.7M | 87.6M | 102.9M | 108.0M | |
| Total Current Liabilities | 92.3M | 105.7M | 103.7M | 105.5M | 150.0M | 157.5M | |
| Total Stockholder Equity | (840.6M) | (1.0B) | (1.2B) | (1.5B) | (455.5M) | (432.8M) | |
| Property Plant And Equipment Net | 7.3M | 7.1M | 8.7M | 15.4M | 21.0M | 22.0M | |
| Net Debt | (29.5M) | (147.4M) | 88.8M | 436.7M | 736.3M | 773.1M | |
| Retained Earnings | (840.6M) | (1.0B) | (1.2B) | (1.5B) | (1.7B) | (1.6B) | |
| Accounts Payable | 14.0M | 18.7M | 27.8M | 14.4M | 20.9M | 21.9M | |
| Cash | 114.2M | 272.1M | 504.4M | 304.8M | 112.4M | 65.7M | |
| Non Current Assets Total | 10.9M | 10.9M | 22.0M | 33.5M | 21.0M | 24.6M | |
| Cash And Short Term Investments | 136.2M | 300.4M | 514.4M | 442.4M | 390.8M | 410.3M | |
| Common Stock Shares Outstanding | 115.6M | 167.3M | 179.1M | 185.9M | 192.2M | 201.8M | |
| Liabilities And Stockholders Equity | (703.6M) | (669.5M) | (512.4M) | (610.0M) | 517.0M | 542.8M | |
| Non Current Liabilities Total | 44.7M | 248.3M | 591.4M | 739.1M | 822.5M | 863.6M | |
| Other Current Assets | 4.4M | 5.5M | 10.0M | 12.6M | 19.5M | 20.5M | |
| Other Stockholder Equity | (1.6M) | (1.8M) | (2.0M) | (1.9M) | 1.2B | 1.3B | |
| Total Liab | 137.0M | 354.0M | 695.1M | 844.6M | 972.5M | 1.0B | |
| Property Plant And Equipment Gross | 7.3M | 7.1M | 8.7M | 25.0M | 19.1M | 20.1M | |
| Total Current Assets | 164.3M | 323.8M | 566.1M | 516.5M | 496.0M | 520.8M | |
| Accumulated Other Comprehensive Income | 39K | 3K | 177K | 26K | 1.3M | 1.4M | |
| Short Term Debt | 40.0M | 31.2M | 1.8M | 2.4M | 26.2M | 27.5M | |
| Non Currrent Assets Other | 3.6M | 3.8M | 6.5M | (33.5M) | 12.0M | 7.6M | |
| Common Stock Total Equity | 1.1M | 1.5M | 1.8M | 1.8M | 2.1M | 2.2M | |
| Short Term Investments | 22.1M | 28.2M | 3.2M | 119.5M | 278.3M | 292.3M | |
| Common Stock | 1.5M | 1.8M | 1.8M | 1.9M | 2.1M | 2.2M | |
| Current Deferred Revenue | 2.1M | 150K | 1.4M | 1.2M | 1.1M | 1.0M | |
| Property Plant Equipment | 7.3M | 7.1M | 15.2M | 15.4M | 17.7M | 18.6M | |
| Other Assets | 2.0M | 978K | 588.2M | 550M | 632.5M | 664.1M | |
| Net Receivables | 22.1M | 8.6M | 29.4M | 50.6M | 57.0M | 59.8M | |
| Inventory | 1.6M | 7.0M | 15.8M | 27.5M | 28.7M | 30.1M | |
| Net Tangible Assets | 82.9M | 109.3M | (147.0M) | (294.6M) | (265.1M) | (251.9M) | |
| Long Term Debt | 41.3M | 119.7M | 585.5M | 733.3M | 811.3M | 851.8M | |
| Retained Earnings Total Equity | (732.0M) | (840.6M) | (1.0B) | (1.2B) | (1.1B) | (1.0B) | |
| Long Term Debt Total | 28.1M | 41.3M | 119.7M | 136.1M | 156.5M | 164.3M | |
| Capital Surpluse | 780.4M | 877.3M | 1.0B | 1.1B | 1.3B | 745.7M |
BioCryst Pharmaceuticals Investors Sentiment
The influence of BioCryst Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in BioCryst. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to BioCryst Pharmaceuticals' public news can be used to forecast risks associated with an investment in BioCryst. The trend in average sentiment can be used to explain how an investor holding BioCryst can time the market purely based on public headlines and social activities around BioCryst Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
BioCryst Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for BioCryst Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average BioCryst Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on BioCryst Pharmaceuticals.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards BioCryst Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, BioCryst Pharmaceuticals' short interest history, or implied volatility extrapolated from BioCryst Pharmaceuticals options trading.
Pair Trading with BioCryst Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if BioCryst Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in BioCryst Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving against BioCryst Stock
| 0.74 | ACB | Aurora Cannabis Trending | PairCorr |
| 0.73 | CGC | Canopy Growth Corp Trending | PairCorr |
| 0.66 | XFOR | X4 Pharmaceuticals Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.58 | ELEV | Elevation Oncology Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to BioCryst Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace BioCryst Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back BioCryst Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling BioCryst Pharmaceuticals to buy it.
The correlation of BioCryst Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as BioCryst Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if BioCryst Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for BioCryst Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioCryst Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy BioCryst Stock please use our How to Invest in BioCryst Pharmaceuticals guide.You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for BioCryst Stock analysis
When running BioCryst Pharmaceuticals' price analysis, check to measure BioCryst Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioCryst Pharmaceuticals is operating at the current time. Most of BioCryst Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of BioCryst Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioCryst Pharmaceuticals' price. Additionally, you may evaluate how the addition of BioCryst Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is BioCryst Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioCryst Pharmaceuticals. If investors know BioCryst will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioCryst Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.18) | Revenue Per Share 1.724 | Quarterly Revenue Growth 0.174 | Return On Assets (0.12) | Return On Equity (19.25) |
The market value of BioCryst Pharmaceuticals is measured differently than its book value, which is the value of BioCryst that is recorded on the company's balance sheet. Investors also form their own opinion of BioCryst Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is BioCryst Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioCryst Pharmaceuticals' market value can be influenced by many factors that don't directly affect BioCryst Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioCryst Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if BioCryst Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioCryst Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.